

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934**

Date of Report (date of earliest event reported): August 18, 2021

Natus Medical Incorporated
(Exact name of registrant as specified in its charter)

000-33001
(Commission File Number)

Delaware
(State or other jurisdiction
of Incorporation)

77-0154833
(I.R.S. Employer
Identification No.)

6701 Koll Center Parkway, Suite 120
Pleasanton, CA 94566
(Address of principal executive offices) (Zip Code)

925-223-6700
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	NTUS	The Nasdaq Stock Market LLC (The Nasdaq Global Select Market)

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On August 18, 2021, the board of directors (the "Board") of Natus Medical Incorporated (the "Company") appointed Bryant M. Moore, Ph.D. and Eric J. Guerin to serve as directors on the Board, effective as of August 18, 2021. Mr. Moore and Mr. Guerin were each granted restricted stock valued at \$150,000 upon appointment to the Board. There are no arrangements or understanding between either Mr. Moore or Mr. Guerin and any other person pursuant to which they were selected as directors. The Board has determined that Mr. Moore and Mr. Guerin are each independent and have no material direct or indirect interest in a related party transaction, which requires disclosure pursuant to Rule 404(a) of Regulation S-K.

On August 18, 2021, the Company issued a press release announcing the appointment of Mr. Moore and Mr. Guerin to the Board. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1 104	Press release dated August 18, 2021, regarding the appointment of Mr. Moore and Mr. Guerin to the Company's Board of Directors. The cover page from this Current Report on Form 8-K, formatted in Inline XBRL (included as Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NATUS MEDICAL INCORPORATED
(Registrant)

Dated: August 18, 2021

By: /s/ B. Drew Davies
Executive Vice President and Chief Financial Officer



Bryant M. Moore, Ph.D. and Eric J. Guerin Appointed to Natus Board of Directors

PLEASANTON, Calif. (August 18, 2021) - Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced the appointments of Bryant M. Moore, Ph.D. and Eric J. Guerin to the Company’s Board of Directors. With these appointments, the Natus Board will be expanded to eight members.

“We are pleased to welcome Bryant and Eric to the Natus Board and look forward to benefitting from their medical device experience and business counsel as we move beyond ‘One Natus’ to a more focused growth-oriented strategy,” said Joshua H. Levine, Chairperson of the Board of Directors.

Dr. Moore has served as the Director of Strategic partnerships at the University of North Carolina’s Office of Technology Commercialization since 2015. Prior to his current role, Dr. Moore served as the Global Head of Refractive R&D at Abbott Laboratories and he served in multiple leadership roles in research and development at Medtronic. Dr. Moore brings decades of significant leadership experience in technology assessment, research, new product development, and platform technology management that will support Natus’ efforts in innovation and portfolio management.

“I am excited to join the Natus Board and help the Company achieve long term growth through a robust innovation pipeline complemented by external acquisition,” said Dr. Moore.

Mr. Guerin serves as Chief Financial Officer of CDK Global, Inc., the largest provider of automotive dealership solutions including retailing, CRM, financing, parts and service, IT infrastructure and dealership operations. Prior to this current role, Mr. Guerin served in financial leadership and business development roles at Corning Incorporated, Flowserve Corporation, Alcon and Johnson & Johnson. Mr. Guerin brings significant financial and business experience with large, complex medical device organizations as well as experience in innovative service and subscription business models to the Board.

“Natus’ neurodiagnostic portfolio is a market leader, and I am looking forward to joining the Board to help the Company build on its core platforms to offer comprehensive solutions to healthcare customers,” said Mr. Guerin.

“Bryant and Eric are joining Natus at an exciting time and will be invaluable resources to the Company as we strengthen internal product development and other growth-oriented business processes,” said Jonathan Kennedy, President and Chief Executive Officer.

About Natus Medical Incorporated

Natus is a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages. Additional information about Natus Medical can be found at www.natus.com.

Natus Medical Incorporated

B. Drew Davies
Executive Vice President and Chief Financial Officer
(925) 223-6700
InvestorRelations@Natus.com